Silencing the receptor of activated C-kinase 1 (RACK1) suppresses tumorigenicity in epithelial ovarian cancer \textit{in vitro} and \textit{in vivo}

YANG LIN, MANHUA CUI, HONG TENG, FENGWEN WANG, WEI YU and TIANMIN XU

Department of Gynaecology and Obstetrics, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China

Received November 11, 2013; Accepted December 18, 2013

DOI: 10.3892/ijo.2014.2274

Abstract. Epithelial ovarian cancer (EOC) is a fatal disease for women due to lack of effective diagnostic biomarkers and therapeutic targets. Thus, it is important to identify and develop specific markers to formulate novel therapeutic methods for advanced and recurrent ovarian cancer. We found that the receptor of activated C-kinase 1 (RACK1) was elevated in most EOCs compared to normal ovarian tissue, and its expression levels correlated with key pathological characteristics including clinical stage and metastasis by quantitative PCR and immunohistochemistry. In addition, we found that downregulation of RACK1 expression using an RNA silencing approach in SKVO3 tumor cells significantly suppressed the proliferation, migration and invasion \textit{in vitro} and tumor growth \textit{in vivo}. Furthermore, it is found that RACK1 silencing was able to significantly suppress constitutive phosphorylation of Akt and MAPK, which may contribute to the inhibition of tumor growth. These results suggest that RACK1 can act as a new promising diagnostic biomarker and a potential anti-cancer therapeutic target for EOC.

Introduction

Epithelial ovarian cancer (EOC) is one of the most common fatal tumors of the female reproductive tract, and accounts for 90% of the incidence and the majority of deaths due to this malignancy (1-3). High mortality rates for ovarian cancer are mainly attributed to the late stage diagnosis of disease because almost 60-65% of ovarian cancer cases are first diagnosed when cancer has already metastasized beyond the confines of the ovarian tissue. Despite the promise for better outcomes in recurrent EOC and advanced-stage ovarian cancer through chemosensitivity or biologic therapies, abdominal recurrence remains a serious clinical issue due to poor prognosis (4).

Therefore, it is important to identify and develop specific markers to formulate novel therapeutic methods for advanced and recurrent ovarian cancer.

The receptor of activated C-kinase 1 (RACK1) was first identified as an anchoring protein for the conventional protein kinase C (PKC) (5). Several signal pathways were regulated by RACK1 interaction with protein kinases C family members, such as PKCα and PKCβII (6-9). RACK1 has been involved in a series of cellular processes including regulation of protein translation (10,11), tissue development (12-14) cellular stress (15) and mammalian circadian clock (7). Importantly, it was expressed in some cancer cells and is involved in cancer progression (16-19). Shi et al found that RACK1 expression was upregulated in non-small cell lung cancer (NSCLC) samples, silencing RACK1 dramatically inhibited \textit{in vivo} tumor growth and metastasis by blocking the sonic hedgehog signaling pathway (16). It has been reported that RACK1 downregulates levels of the pro-apoptotic protein Fem1b in metastatic, apoptosis-resistant colon cancer cells, which may promote apoptosis-resistance during progression of colon cancer (17). Cao et al found that RACK1 is an independent prognosis-related factor and promotes breast carcinoma proliferation and invasion/metastasis \textit{in vitro} and \textit{in vivo} (18). These studies implied that RACK1 could promote carcinoma proliferation and invasion/metastasis, and the down-regulated RACK1 was able to induce cancer cell apoptosis and inhibited cancer cell proliferation and migration. However, to our knowledge, the effect of RACK1 expression on tumorigenicity in ovarian cancer \textit{in vivo} and \textit{in vitro} has rarely been reported (19).

In this study, we investigate the effect of downregulating the RACK1 expression on cell growth, cell apoptosis, cell migration and tumor growth in human ovarian cancer \textit{in vivo} and \textit{in vitro}.

Materials and methods

Patients and immunohistochemistry. Paraffin-embedded tissue samples from 50 EOC patients, diagnosed at the Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Jilin University (Changchun, China) from December 2010 to September 2012 were studied. Clinicopathological information was collected from clinical data of EOC patients (Table I). Tumors were staged according to the tumor node metastasis staging system of the International Union against Cancer (UICC). This study was approved by the ethics committee of...
siRNA design and conduct. Templates of small interfering RNA (siRNA) against RACK1 were designed according to the instructions in the Silencer siRNA Construction kit (Ambion Inc., Austin, TX, USA) and synthesized (Invitrogen, Carlsbad, CA, USA). Sequences of the siRNA1 templates are: sense, 5'-AAGCAAGAGTTATCGATACCCTGTC-3'; and antisense, 5'-AAATCTGAACTCTGTGCTGTC-3'. Sequences for the scrambled control are: sense, 5'-CACAAAGTCGAAACGCTAATGTCCCCCCCTGTC-3'; and antisense, 5'-ACAAATGTTCCATGGCCGTCGTC-3'. Sequences of the siRNA2 templates are: sense, 5'-TATATGGAATTCCTC-3'; and antisense, 5'-AACCGCTTGACATTCACTGCCTGTC-3'. The cDNAs corresponding to the three siRNAs and NC were subcloned into the replication-deficient, self-inactivating lentiviral expression vector pGCSIL-RNAi-GFP (Shanghai Gene Chem, Shanghai, China). Lentivirus containing siRNA was produced according to Coleman et al as previously described (21). The final titer of siRNA1 siRNA2 and negative control (NC) were 4x10^8, 5x10^8 and 1x10^8 TU/ml, respectively.

Cell viability analysis. MTT assay was used to determine the effect of siRNA-RACK1 on the proliferation of cells. SKOV3 cells were incubated at a concentration of 5x10^5 cell/well in a 96-well plate, and grown at 37°C, 5% CO2 incubator until cell adherence. The cells on the culture plate were divided into groups on the basis of parallel lines after an overnight incubation rate (%) = [1- (average absorbance of experimental group/average absorbance of blank control group)] x 100%.

Apoptosis analysis. SKOV3 cells were cultured in 6-well plates in RPMI-1640 with 10% FBS medium and were treated with different siRNA for 24, 48 and 72 h. The cover slips were washed three times with phosphate-buffered saline (PBS) and single cell suspensions were fixed in 1% PBS. Cells were stained with 100 µg/ml acridine orange (AO) and 100 µg/ml ethidium bromide (EB) for 1 min. Then cells were observed under fluorescence microscope. At least 200 cells were counted and the percentage of apoptotic cells was determined. Triplicates were performed in all experiments, and experiments were performed five times.

Cell migration assay. The migration assay was performed using a 12-well Boyden Chamber (Neuro Probe, Gaithersburg, MD, USA) with an 8 µm pore size. About 1x10^5 cells were seeded into the upper wells of the Boyden Chamber and incubated for 6 h at 37°C in medium containing 1% FBS. Medium containing 10% FBS was used as a chemoattractant in the lower wells. Cells that did not migrate through the pores of the Boyden Chamber were manually removed with a rubber instrument. Cells that migrated to the lower side of the membrane were stained with hematoxylin and eosin and photographed using an inverted microscope.

Invasion analysis. Cells (1x10^5/well) were seeded in a Cell Culture Insert (8 µm pore size; Falcon, BD Biosciences, San Jose, CA, USA), precoated with 25 µl of Matrigel (2-3 mg/ml protein), and then placed in a 24-well plate (Falcon, BD Biosciences). After cells had been cultured at 37°C for 40 h, they were fixed and stained with 0.5% crystal violet. The cells on the top of the cell culture insert were removed

### Table I. The correlation of RACK1 overexpression with clinicopathologic features of epithelial ovarian cancer.

<table>
<thead>
<tr>
<th>Clinical factors</th>
<th>Positive</th>
<th>Negative</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age &lt;50 (n=20)</td>
<td>14</td>
<td>6</td>
<td>0.944</td>
</tr>
<tr>
<td>≥50 (n=30)</td>
<td>22</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No (n=26)</td>
<td>15</td>
<td>11</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Yes (n=24)</td>
<td>21</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Clinical stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-I (n=35)</td>
<td>22</td>
<td>13</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>III-IV (n=15)</td>
<td>14</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Tumor size &lt;1.0 cm (n=28)</td>
<td>20</td>
<td>8</td>
<td>0.457</td>
</tr>
<tr>
<td>≥1.0 cm (n=22)</td>
<td>16</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1 (n=15)</td>
<td>11</td>
<td>4</td>
<td>0.896</td>
</tr>
<tr>
<td>G2 (n=24)</td>
<td>18</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>G3 (n=11)</td>
<td>7</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

To detect the expression and localization of RACK1 protein in ovarian tumor tissue, immunohistochemistry was performed using an SP reagent kit (Tiangen, Beijing, China) according to the manufacturer’s instructions. The degree of immunoreactivity was assessed according to Campo et al (20). Immunoreactivity was measured semiquantitatively using a scale from 0 to 3 score, where score 0 represents no immunostaining, 1 represents fewer than 25% cells reactive, 2 represents 25-50% of the cells reactive and 3 represents more than 50% of the cells reactive. Values of 0 and 1 were considered to indicate negative staining, and 2 and 3 to indicate positive staining. Five cases with discordant results were re-evaluated to obtain agreement.

Jilin Hospital and an informed consent was obtained from all participants.
by wiping with a cotton swab, and cell invasion was observed with an immunofluorescence microscope by counting the cells that had invaded into the lower of the cell culture insert. All experiments were performed in triplicate.

**Tumor xenograft assay.** All animal experiments were performed in accordance with institutional guidelines, following a protocol approved by the Ethics Committees of the Disease Model Research Center, The Second Hospital of Jilin University. About 6 weeks old female BALB mice were maintained under specific pathogen-free conditions and provided with food and water *ad libitum*. All the animals were fed with a normal pellet diet one week prior to the experimentation. *In vitro* cultured SKOV3 cells were injected s.c. into the right supra scapula region of the mice. Tumor volume was calculated by formula: volume = length x width^2/2. When tumors grew to an average volume of 75 mm³, mice were randomly divided into siRNA1, siRNA2, NC group (n=10 in each) and by administered siRNA1, siRNA2, and NC plus PBS in a total volume of 15 µl (5 µl virus plus 10 µl PBS) one time a week for 21 days, respectively. When control mice started to succumb to their tumors, the mice in all treatment groups were euthanized. After the mice had been sacrificed, the tumors were removed and directly embedded in an optimal cutting temperature (OCT) medium at -80°C.

**Real-time quantitative PCR.** Total RNA was isolated from SKOV3 cell lines and ovarian tissues of EOC patients using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. RNA was reverse-transcribed into cDNA using a Primerscript™ RT reagent kit according to the manufacturer's instructions. Real-time quantitative polymerase chain reaction (PCR) was performed with the SYBR-Green fluorescent dye method, and a Rotor Gene 3000 real-time PCR apparatus. Human primer sequences were: RACK1 forward, 5'-TCTCTTT CCAGCGTGGCCATTAGA-3' and reverse, 5'-CCTCGAAGCT TGAGAGATTCCGACAT-3'; β-actin forward, 5'-GATCAT TGCTCCTCCTGAGC-3' and reverse, 5'-ACTCTGCTTGGC TGATCCAC-3'. The PCR conditions were as follows: pre-denaturing at 95°C for 2 min, followed by 45 cycles of denaturation at 95°C for 10 sec, annealing/extension at 60°C for 20 sec. The amplification specificity was checked by melting curve analysis. The 2^−ΔΔCT^ method was used to calculate the relative abundance of target gene expression generated by Rotor-Gene Real-Time Analysis Software 6.1.81. For each cDNA, the target gene mRNA level was normalized to β-actin mRNA level. The experiments were performed three times.

**Western blot analysis.** Cultured cells were washed twice with PBS and lysed by radioimmuno precipitation assay buffer for 30 min on ice. Cell lysates were clarified by centrifugation (10,000 x g, 15 min), and protein concentrations were determined using the Bradford reagent (Sigma). Lysates were separated on 8 or 15% SDS-PAGE; proteins were transferred to Immobilon membrane (Millipore, Bedford, MA, USA) immunoblotted with specific primary antibodies and incubated with corresponding horseradish peroxidase-conjugated secondary antibody. The primary antibodies used in the western blots were: antibodies against Akt, phosphorylated (p)-Akt, MAPK, p-MAPK, anti-RACK1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA). All immunoblots were visualized by enhanced chemiluminescence (Pierce, Rockford, IL, USA).

**Statistical analysis.** The data are expressed as mean ± SEM. Statistical analysis between two samples was performed using Student's t-test. Statistical comparison of more than two groups was performed using one-way ANOVA followed by a Tukey's post hoc test and considered significant at *P*<0.05 or **P**<0.01.

**Results**

**RACK1 is upregulated in EOC and correlates with clinical features of EOC patients.** To identify the potential roles of RACK1 in the development and progression of EOC, we assessed its expression level by real-time polymerase chain reaction (PCR) in 50 pairs of matched ovarian tissue samples. Expression levels of RACK1 were significantly higher in EOC tumors compared with their normal ovarian counterparts (Fig. 1A). Furthermore, elevated levels of RACK1 protein were found in EOC tumors compared with the paired normal tissues from the same patients as shown by immunohistochemical staining (Fig. 1B). Further analysis revealed that the upregulation of
RACK1 protein in EOC samples was positively correlated with both lymph node metastasis and tumor TNM stage (P<0.01, Table I). No correlation occurred between RACK1 protein levels, age, tumor size and histologic grade. These data suggested that RACK1 expression correlates with advanced EOC.

siRACK1 transformed into lentiviral vector efficiency assay. To understand the function of RACK1 in EOC, we used the RNAi-mediated knockdown lentiviral vector to decrease the basal level of RACK1 (knockdown of RACK1) in SKOV3 cells by real-time RT-PCR and western blot analysis. Real-time RT-PCR and western blot analysis results showed that two independent target sequences siRNA1 and siRNA2 markedly decreased the expression of RACK1 compared with the control sequence (Fig. 2). These results demonstrated that siRNA targeting RACK1 significantly silenced RACK1 expression in vitro.

Figure 2. Silencing RACK1 by siRNA inhibits the RACK1 expression in SKVO3 tumor cells. (A) Quantitative real-time PCR analysis of RACK1 after RNAi silencing. (B) Western blot analysis of RACK1 after RNAi silencing. The images are representative results from three independent experiments. *P<0.05, **P<0.01 vs. control.

Figure 3. RACK1 silencing inhibits tumor cell growth and invasion and induces cell apoptosis in vitro. SKOV3 cells were transfected with scrambled control siRNA (control) or RACK1 siRNAs (siRNA1 and siRNA2), as indicated. Downregulation of RACK1 by transfection of siRNA significantly (A) suppressed the proliferation, (B) induced cell apoptosis, and significantly suppressed (C) migration and (D) invasive ability of SKVO3 cells, *P<0.05, **P<0.01 vs. control.
Silencing RACK1 in ovarian cancer cells reduces proliferation, migration and invasion in vitro. Using these two siRNAs, we examined the effects of RACK1 silencing on tumor cell growth in vitro. The anti-proliferative effect of RACK1 silencing on SKOV3 tumor cell were examined using MTT assays. It was found that it significantly inhibited the proliferation of SKOV3 tumor cells compared with control cells (scrambled siRNA) (Fig. 3A). Conversely, RACK1 silencing significantly improved apoptosis of SKOV3 tumor cells compared with control time-dependently, as determined using the AO staining assay (Fig. 3B). Furthermore, the effects of silencing RACK1 on ovarian tumor cell migration and invasion were assessed. As shown in Fig. 3C, silencing RACK1 reduced migration capacity in SKOV3 tumor cells. In addition, cell invasion ability was significantly decreased, when assessed after 48 h by the modified Boyden chamber assays (Fig. 3D). Together, these data indicate that RACK1 plays an important regulatory role in tumor cell growth and migration.

Silencing RACK1 suppresses tumor growth in vivo. To obtain definitive evidence that RACK1 is required for ovarian tumor growth in vivo, we conducted a xenograft assay by injecting the control (si-scrambled) and RACK1-silenced tumor cells subcutaneously into mice and compared the growth rate to solid tumors. Mice were sacrificed and taken out tumor tissue 21 days after treatment. Then tumor weight of the animals was measured. The tumor weight of siRNA group was lower than those of control group (Fig. 4A). We found that tumor volume after RACK1 silencing was significantly slower in SKOV3 tumor cells compared with control cells (Fig. 4B). These results indicate that suppression of RACK1 expression in ovarian tumor cells markedly suppresses their tumorigenicity in mice.

RACK1 silencing inhibits the phosphorylation of Akt and MAPK in vitro. To clarify the molecular mechanisms involved due to downregulation of RACK1 inhibition the growth of human tumor xenografts, in the present study, we focused on the effects of RACK1 silencing on the activation of MAPK, Akt, which participate in the main intracellular signaling required for cell proliferation and survival. As shown in Fig. 5, compared with control siRNAs, RACK1 silencing led to a significant suppression of Akt and MAPK activation. These results indicate that RACK1 silencing inhibits tumor cell growth, to some extent, by suppressing MAPK and Akt-mediated signaling.

Discussion

RACK1, as a crucial scaffold protein, was originally cloned as an anchoring protein for PKC; it plays a critical role in stabilizing the active form of PKC and in permitting its translocation to different sites within a cell (22,23). A large number of literature reveals that RACK1 can associate with various signaling molecules and is involved in the regulation of various cell functions (24-27). Increased RACK1 expression has been reported in lung, colon, breast and hepatocellular carcinomas and human melanomas (28-30). Zhang et al found that increased RACK1 plays an important role in IR/IGF-1R-mediated promotion of anchorage-independent growth of certain ovarian cancer cells (19). However, this study did not focus on RACK1 expression in EOC patients. To our knowledge, in the present study, we
first found that RACK1 was elevated in most EOC compared to normal ovarian tissue, and its expression level correlated with key pathological characteristics including clinical stage and metastasis. Our findings also show that downregulation of RACK1 results in the inhibition of proliferation migration for SKVO3 cells in vitro, and suppression of solid tumor growth in vivo. These results provide evidence that RACK1 is required for tumor growth and that it may be a diagnostic marker.

Previous studies showed that several signal pathways were regulated by RACK1 interaction with protein kinases C family members, such as PKC, Src and IGF-1R (19,22,26). It is widely accepted, that aberrant activation of several PKC isoforms leads to tumorigenesis; thus, as an important stabilizer of PKC activity, RACK1 may play a pivotal role in regulating PKC signaling-related tumor progression (22,23,31). Berns et al showed that RACK1 is upregulated in vascular endothelial cells during angiogenesis and may contribute to tumor growth and spreading (30). Wang et al found that RACK1 silencing significantly attenuated tumor-associated angiogenesis by inhibiting the expression of two critical angiogenic factors (17). Furthermore, Keily et al showed that the proliferation of MCF-7 cells was enhanced by overexpression of RACK1, whereas IGF-1-mediated protection from etoposide-dependent death was greatly reduced (32). Two other groups also reported that knockdown of RACK1 suppressed IGF-1R and androgen receptor-dependent tumor cell growth (33,34). Zhang et al further showed that RACK1 acts as an adaptor protein to facilitate the association of STAT3 with IR/IGF-1R and subsequent phosphorylation and activation of STAT3 specifically (19). Shi et al found that RACK1 activated the sonic hedgehog signaling pathway by interacting with and activating smoothmediated to mediate Gli1-dependent transcription in NSCLC cells (16). These studies show that RACK1 is simultaneously involved in widespread signaling pathways owing to its association with PKC, Src family members, and other multiple pathways related to these proteins appear to be activated in the process of tumor growth. Thus, RACK1 is implicated in a complicated signaling network rather than a simple pathway. In the present study, we focused on the effect of RACK1 on the activation of central players in growth signaling, such as Akt, MAPK, which are often constitutively activated in a variety of cancers and participated in the main intracellular signaling required for cell proliferation and survival (35,36). We found that RACK1 silencing significantly inhibited the phosphorylation of Akt and MAPK to some extent in SKVO3 cells. Which implied that the suppression of Akt- or MAPK-related pathways contributes, at least in part, to the inhibition of tumor growth.

A series of experiments (in vitro and in vivo) were designed to investigate the characteristics of RACK1 and to evaluate its role in ovarian tumorigenesis. Our results show that the silencing of RACK1 induced SKVO3 tumor cell apoptosis, which agrees with the downregulation of RACK1 inducing cell apoptosis in NSCLC (16). However, in contrast with a previous report that overexpression of RACK1 induced apoptosis of HT-29 colon carcinoma cells, partly by inhibiting Src activity (37). Moreover, recent studies showed that RACK1 knockdown inhibited cell growth but did not affect cell apoptosis (17,18). These above studies suggested that RACK1 has opposing effects on cell apoptosis of different types of tumor cells, and the discrepancy may arise from differences the cell types used or in the experimental conditions.

In conclusion, to our knowledge, this is the first full-scale report concerning the association of RACK1 with ovarian carcinoma. The present study demonstrates that RACK1 was elevated in most EOC and its expression level correlated with key pathological characteristics including clinical stage and metastasis and it plays a critical role in tumor growth by affecting cell proliferation and tumor growth in vitro and in vivo. Based on the multiple functions of RACK1 in tumor growth, it may be considered a marker for diagnosis and a potential anticancer therapeutic target.

References


